Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management

References

• Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 2012;26(Suppl 1):S3-6
   PubMed Web of Science ®Google Scholar
• Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013;98:833-44
   PubMed Web of Science ®Google Scholar
• Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sang 2015;108:1-10
   PubMed Web of Science ®Google Scholar
• Harteveld CL, Higgs DR. Alpha-thalassemia. Orphanet J Rare Dis 2010;5:13
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med 2012;2(8):
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Marasella M, Zanforlin N. The natural history of thalassemia intermedia. Ann NY Acad Sci 2010;1202:214-20
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Hemoglobin E syndromes. Hematology Am Soc Hematol Educ Program 2007;:79-83
   PubMedGoogle Scholar
• Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010;115:4331-6
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004;:14-34
   PubMedGoogle Scholar
• Vichinsky EP. Changing patterns of thalassemia worldwide. Ann NY Acad Sci 2005;1054:18-24
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Treadwell M, Yamashita R, et al. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann NY Acad Sci 2005;1054:457-61
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005;80:70-4
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β thalassemia intermedia. Blood Cells Mol Dis 2013;51:35-8
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010;8:54-9
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res 2012;130:695-702
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Balassopoulou A, Boutou E, et al. Pregnancy in beta-thalassemia intermedia: 20-year experience of a Greek thalassemia center. Eur J Haematol 2014;93:492-9
   PubMed Web of Science ®Google Scholar
• Lal A, Goldrich MJ, Haines DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011;364:710-18
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000;111:467-73
   PubMed Web of Science ®Google Scholar
• Tantawy AA, Adly AA, Mahdy SA, Kamel GZ. Spinal cord compression and extramedullary hematopoiesis in young Egyptian beta-thalassemia patients. Hemoglobin 2009;33:448-62
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: four case reports. Hematology 2015;20:53-7
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007;49:329-32
   PubMed Web of Science ®Google Scholar
• Haines D, Martin M, Carson S, et al.; Thalassemia Clinical Research Network. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 2013;160:680-7
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol 2010;150:486-9
   PubMed Web of Science ®Google Scholar
• Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009;52:486-90
   PubMed Web of Science ®Google Scholar
• Choy J, Foote D, Bojanowski J, et al. Outreach strategies for southeast Asian communities: experience, practice, and suggestions for approaching southeast Asian immigrant and refugee communities to provide thalassemia education and trait testing. J Pediatr Hematol Oncol 2000;22:588-92
   PubMed Web of Science ®Google Scholar
• Lorey F, Cunningham G, Vichinsky EP, et al. Universal newborn screening for Hb H disease in California. Genet Test 2001;5:93-100
   PubMedGoogle Scholar
• Hoppe CC. Newborn screening for non-sickling hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2009;:19-25
   PubMedGoogle Scholar
• Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005;116:e818-25
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Neumayr L, Trimble S, et al.; CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014;54:972-81; quiz 971
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Tyan P, Rodmai S, Taher AT. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J Rare Dis 2014;9:131
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation, 2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK190453
   Google Scholar
• Cui J, Azimi M, Baysdorfer C, et al. Application of multiplex ligation-dependent probe amplification to screen for β-globin cluster deletions: detection of two novel deletions in a multi ethnic population. Hemoglobin 2013;37:241-56
   PubMed Web of Science ®Google Scholar
• Haddad A, Tyan P, Radwan A, et al. Beta-thalassemia intermedia: a bird’s eye view. Turk J Haematol 2014;31:5-16
   PubMed Web of Science ®Google Scholar
• Vogiatzi MG, Macklin EA, Fung EB, et al.; Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009;24:543-57
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115:1886-92
   PubMed Web of Science ®Google Scholar
• Fung EB, Xu Y, Trachtenberg F, et al.; Thalassemia Clinical Research Network. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet 2012;112:980-90
   PubMed Web of Science ®Google Scholar
• Fung EB, Kwiatkowski JL, Huang JN, et al. Zinc supplementation improves bone density in patients with thalassemia: a double blind, randomized, placebo-controlled trial. Am J Clin Nutr 2013;98:960-71
   PubMed Web of Science ®Google Scholar
• Fung EB, Vichinsky EP, Kwiatkowski JL, et al. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 2011;48:1305-12
   PubMed Web of Science ®Google Scholar
• Giusti A. Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab 2014;32:606-15
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Levine L, Bhatia S, et al. Standards of Care Guidelines for Thalassemia, 2012. Oakland, CA: Children’s Hospital & Research Cancer Oakland. Available at: https://thalassemia.com/documents/SOCGuidelines2012.pdf [Last accessed 15 August 2014]
   Google Scholar
• Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000;96:3369-73
   PubMed Web of Science ®Google Scholar
• Haidar R, Mhaidli H, Musallam KM, Taher AT. The spine in β-thalassemia syndromes. Spine (Phila Pa 1976) 2012;37:334-9
   PubMed Web of Science ®Google Scholar
• Esfandbod M, Malekpour M. Thalassemia and spinal cord compression in pregnancy. CMAJ 2010;182:E798
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with β thalassemia intermedia. Ann Hematol 2012;91:1833-8
   PubMed Web of Science ®Google Scholar
• Brousse V, Hertz-Pannier L, Consigny Y, et al. Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease? Ann Hematol 2009;88:785-8
   PubMed Web of Science ®Google Scholar
• Riddington C, Wang W. Blood transfusion for preventing stroke in people with sickle cell disease. Cochrane Database Syst Rev 2002;1:CD003146. Update in: Cochrane Database Syst Rev 2013;11:CD003146
   PubMedGoogle Scholar
• Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann NY Acad Sci 2010;1202:205-13
   PubMed Web of Science ®Google Scholar
• Morris CR, Kim HY, Wood J, et al. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica 2013;98:1359-67
   PubMed Web of Science ®Google Scholar
• Derchi G, Balocco M, Bina P, et al. Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica 2014;99:e17-8
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011;96:1605-12
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann NY Acad Sci 2010;1202:231-6
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96:488-91
   PubMed Web of Science ®Google Scholar
• Danjou F, Cabantchik ZI, Origa R, et al. A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica 2014;99:e38-40
   PubMed Web of Science ®Google Scholar
• Vichinsky EP. Emerging therapy in hemoglobinopathies: lessons from the past and optimism for the future. Hematol Oncol Clin North Am 2014;28:xiii-xviii
   PubMed Web of Science ®Google Scholar
• Barton JC. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders. IDrugs 2007;10:270-81
   PubMed Web of Science ®Google Scholar
• Breda L, Rivella S. Modulators of erythropoiesis emerging therapies for hemoglobinopathies and disorders of red cell production. Hematol Oncol Clin North Am 2014;28:375-86
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Fleming MD. Modulation of hepcidin as therapy for primary and secondary iron overload disorders preclinical models and approaches. Hematol Oncol Clin North Am 2014;28:387-401
   PubMed Web of Science ®Google Scholar
• Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E. Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. Br J Haematol 2011;154:281-4
   PubMed Web of Science ®Google Scholar
• Perrine SP, Pace BS, Faller DV. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Hematol Oncol Clin North Am 2014;28:233-48
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008;80:168-76
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62
   PubMed Web of Science ®Google Scholar
• Ferriprox [prescribing information]. Rockville, MD: ApoPharma USA Inc., April 2012
   Google Scholar
• Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305-10
   PubMed Web of Science ®Google Scholar
• Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 2006;133:198-205
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154:387-97
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970-7
   PubMed Web of Science ®Google Scholar
• Exjade [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, October 2013
   Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-17
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, et al.; Deferasirox in Sickle Cell Investigators. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood 2013;121:2199-212; quiz 2372
   PubMed Web of Science ®Google Scholar
• Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 2014;89:766-70
   PubMed Web of Science ®Google Scholar
• Piga AG, Perrotta S, Melpignano A, et al. ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-thalassemia: preliminary results from a phase 2 study. Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. December 6-9, 2014; San Francisco, California. 2014;124:53
   Google Scholar
• Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009;16:187-94
   PubMed Web of Science ®Google Scholar
• Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol 2013;88:409-15
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013;92:1485-93
   PubMed Web of Science ®Google Scholar